E. Paul

833 total citations
10 papers, 386 citations indexed

About

E. Paul is a scholar working on Oncology, Molecular Biology and Neurology. According to data from OpenAlex, E. Paul has authored 10 papers receiving a total of 386 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Oncology, 3 papers in Molecular Biology and 3 papers in Neurology. Recurrent topics in E. Paul's work include Nonmelanoma Skin Cancer Studies (3 papers), CAR-T cell therapy research (2 papers) and Muscle Physiology and Disorders (2 papers). E. Paul is often cited by papers focused on Nonmelanoma Skin Cancer Studies (3 papers), CAR-T cell therapy research (2 papers) and Muscle Physiology and Disorders (2 papers). E. Paul collaborates with scholars based in United Kingdom, United States and France. E. Paul's co-authors include Allan Hackshaw, P. Ward, G Slavin, R O McKeran, Richard H. J. Beǵent, Heleni Mastoroudes, Daniel Hochhauser, Flora Ng, Jonathan Tibballs and Allan R. Mayer and has published in prestigious journals such as British Journal of Cancer, The Journal of Pathology and Journal of Clinical Pathology.

In The Last Decade

E. Paul

10 papers receiving 357 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
E. Paul United Kingdom	9	176	81	66	65	64	10	386
Dimitrios Kassimos Greece	9	59 0.3×	55 0.7×	15 0.2×	49 0.8×	26 0.4×	18	429
Jean Chidiac France	11	72 0.4×	19 0.2×	47 0.7×	63 1.0×	59 0.9×	23	371
Max O. Meneveau United States	14	318 1.8×	34 0.4×	21 0.3×	68 1.0×	54 0.8×	35	647
Sarah S. Burns United States	15	85 0.5×	128 1.6×	29 0.4×	167 2.6×	36 0.6×	28	468
Friso L. H. Muntinghe Netherlands	9	115 0.7×	36 0.4×	7 0.1×	61 0.9×	64 1.0×	19	410
John R. Schoenfelder United States	10	101 0.6×	62 0.8×	8 0.1×	29 0.4×	60 0.9×	14	463
Judit Laki Hungary	13	57 0.3×	40 0.5×	7 0.1×	96 1.5×	63 1.0×	18	566
C Brambilla France	8	73 0.4×	29 0.4×	39 0.6×	64 1.0×	153 2.4×	30	327
Neyran Kertmen Türkiye	11	333 1.9×	35 0.4×	6 0.1×	90 1.4×	100 1.6×	56	491
Adrienne Melck Canada	13	104 0.6×	44 0.5×	20 0.3×	210 3.2×	64 1.0×	31	704

Countries citing papers authored by E. Paul

Since Specialization

Citations

This map shows the geographic impact of E. Paul's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. Paul with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. Paul more than expected).

Fields of papers citing papers by E. Paul

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E. Paul. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. Paul. The network helps show where E. Paul may publish in the future.

Co-authorship network of co-authors of E. Paul

This figure shows the co-authorship network connecting the top 25 collaborators of E. Paul. A scholar is included among the top collaborators of E. Paul based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E. Paul. E. Paul is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

1.

Paul, E., Andreas Kuznik, Chieh-I Chen, et al.. (2021). Assessing the Value of Cemiplimab for Adults With Advanced Cutaneous Squamous Cell Carcinoma: A Cost-Effectiveness Analysis. Value in Health. 24(3). 377–387. 17 indexed citations

2.

Paul, E., Shannon Cope, Chieh-I Chen, et al.. (2021). Cost-effectiveness analysis of cemiplimab vs pembrolizumab for treatment of advanced cutaneous squamous cell carcinoma. Journal of Managed Care & Specialty Pharmacy. 27(11). 1513–1525. 4 indexed citations

3.

Ng, Flora, Heleni Mastoroudes, E. Paul, et al.. (2007). A Comparison of Hickman Line- and Port-a-Cath-associated Complications in Patients with Solid Tumours Undergoing Chemotherapy. Clinical Oncology. 19(7). 551–556. 71 indexed citations

4.

Hackshaw, Allan & E. Paul. (2003). Breast self-examination and death from breast cancer: a meta-analysis. British Journal of Cancer. 88(7). 1047–1053. 157 indexed citations

5.

Thomas, D. G. T., John L. Darling, E. Paul, et al.. (1985). Assay of anti-cancer drugs in tissue culture: Relationship of relapse free interval (RFI) and in vitro chemosensitivity in patients with malignant cerebral glioma. British Journal of Cancer. 51(4). 525–532. 29 indexed citations

6.

Illig, L, et al.. (1984). Epifocal dinitrochlorobenzene therapy in malignant melanoma (experience during the last eight years).. PubMed. 4(4-5). 293–8. 14 indexed citations

7.

Aigner, Kornelia, H. Breithaupt, M Hundeiker, et al.. (1983). Isolated extremity perfusion with DTIC. An experimental and clinical study.. PubMed. 3(2). 87–93. 12 indexed citations

8.

McKeran, R O, et al.. (1980). Hypothyroid myopathy. A clinical and pathological study. The Journal of Pathology. 132(1). 35–54. 49 indexed citations

9.

McKeran, R O, P. Ward, G Slavin, & E. Paul. (1979). Central nuclear counts in muscle fibres before and during treatment in hypothyroid myopathy. Journal of Clinical Pathology. 32(3). 229–233. 16 indexed citations

10.

Spiers, A. S. D., P. D. Roberts, G. W. Marsh, et al.. (1975). Acute lymphoblastic leukaemia: cyclical chemotherapy with three combinations of four drugs (COAP-POMP-CART regimen).. BMJ. 4(5997). 614–617. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact